Scholar Rock Holding (SRRK) Change in Acquisitions & Divestments (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Change in Acquisitions & Divestments of $20.0 million for Q1 2026, down 78.47% year-over-year from $92.9 million in Q1 2025, and down 48.72% quarter-over-quarter from $39.0 million in Q4 2025.
Analysis
Scholar Rock Holding (SRRK) Change in Acquisitions & Divestments (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Change in Acquisitions & Divestments history runs 10 years deep, the most recent figure standing at $20.0 million for Q1 2026.
- In Q1 2026, Change in Acquisitions & Divestments fell 78.47% year-over-year to $20.0 million; the TTM figure through Mar 2026 stood at $244.4 million (up 1.12% YoY), while the FY2025 annual figure was $317.3 million, up 46.09% from the prior year.
- Change in Acquisitions & Divestments for Q1 2026 stood at $20.0 million, down from $39.0 million in the prior quarter.
- The five-year high for Change in Acquisitions & Divestments was $106.9 million in Q2 2025, with the low at $10.0 million in Q1 2022.
- The 5-year median for Change in Acquisitions & Divestments is $68.4 million (2024), against an average of $59.8 million.
- The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments tumbled 81.82% in 2022, then jumped 800.0% in 2023.
- Scholar Rock Holding's Change in Acquisitions & Divestments stood at $10.0 million in 2022, then surged by 690.0% to $79.0 million in 2023, then tumbled by 80.89% to $15.1 million in 2024, then surged by 158.28% to $39.0 million in 2025, then tumbled by 48.72% to $20.0 million in 2026.
- Business Quant data shows SRRK's Change in Acquisitions & Divestments at $20.0 million in Q1 2026, $39.0 million in Q4 2025, and $78.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Scholar Rock Holding | 7.24 Bn | 7.24 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 37.50 Mn |
| Mar 31, 2026 | 20.00 Mn |
| Dec 31, 2025 | 39.00 Mn |
| Sep 30, 2025 | 78.50 Mn |
| Jun 30, 2025 | 106.90 Mn |
| Mar 31, 2025 | 92.90 Mn |
| Dec 31, 2024 | 15.10 Mn |
| Sep 30, 2024 | 49.60 Mn |
| Jun 30, 2024 | 84.10 Mn |
| Mar 31, 2024 | 68.40 Mn |
| Dec 31, 2023 | 79.00 Mn |
| Sep 30, 2023 | 73.00 Mn |
| Jun 30, 2023 | 90.00 Mn |
| Mar 31, 2023 | 90.00 Mn |
| Dec 31, 2022 | 10.00 Mn |
| Sep 30, 2022 | 65.00 Mn |
| Jun 30, 2022 | 45.00 Mn |
| Mar 31, 2022 | 10.00 Mn |
| Dec 31, 2021 | 30.00 Mn |
| Sep 30, 2021 | 35.00 Mn |